Aortic Valve Stenosis Clinical Trial
— DIRECTOfficial title:
The preDIlatation in tRanscathEter aortiC Valve implanTation Trial
NCT number | NCT02448927 |
Other study ID # | DIRECT Trial |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 2015 |
Est. completion date | May 2, 2018 |
Verified date | September 2019 |
Source | National and Kapodistrian University of Athens |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a randomized trial that will evaluate the role of balloon aortic valvuloplasty (BAV) on the outcome of patients undergoing transcatheter aortic valve implantation (TAVI) procedure. Patients will undergo a physical exam, coronary angiography and computed tomography angiography before TAVI. The randomization for direct or non-direct TAVI ( with BAV or without BAV) will take place 24 hours prior to the procedure by the core lab at Hippokration Hospital in Athens. The same lab will analyze in blind fashion the results of all the imaging modalities for each patient. The patients will be followed during the hospital stay and at 30 days and 1 year thereafter by echocardiography. The procedure of predilatation will be at the operator's discretion.
Status | Completed |
Enrollment | 170 |
Est. completion date | May 2, 2018 |
Est. primary completion date | May 2, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Diameter of >5mm for Evolut R and >6mm for CoreValve of the vessel. 2. Aortic valve diameter of =20mm and =29mm as measured by echo. 3. Ascending aorta diameter = 43mm at the sinotubular junction. 4. Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram. 5. STS score of = 8 OR LogEuroSCORE> 20%, OR - 80 years old OR - 65 years old with 1 or 2 (but not more than two) from the following criteria: - Liver cirrhosis (Class A or B). - Pulmonary insufficiency: VMS<1 liter. - Previous heart surgery (CABG, vascular surgery). - Porcelain aorta. - Pulmonary artery systolic pressure >60 mmHg and high risk for heart surgery. - Relapsing pulmonary embolism. - Right ventricular insufficiency. - Thoracic wall injuries that contraindicate an open heart surgery. - History of radiation therapy of the mediastinum. - Connective tissue disease that contraindicates an open heart surgery. - Frailty/cachexia. 6. Patients will be informed on the nature of the study and provide written consent. Exclusion Criteria: 1. A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin or heparin and bivalirudin, ticlopidine and clopidogrel, nitinol (titanium or nickel), contrast media 2. Ongoing sepsis, including active endocarditis. 3. Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to Heart Team assessment. 4. Echocardiographic evidence of LV or LA thrombus. 5. Mitral or tricuspid valve insufficiency (> grade II). 6. Previous aortic valve replacement (mechanical or bioprosthetic). 7. Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA). 8. Patients with: Femoral, iliac or aortic vascular disease (stenosis etc) that precludes the insertion of a transcatheter sheath. OR Symptomatic carotid or vertebral artery disease (> 70% stenosis). 9. The patient has a bleeding diathesis, coagulopathy or denies blood transfusion. 10. Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions. 11. Creatinine clearance < 20 ml/min. 12. Active gastritis or ulcer. 13. Pregnancy. 14. Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20%. 15. Unicuspid or bicuspid aortic valve. 16. Mixed aortic valve disease (aortic stenosis and aortic regurgitation> 2+). 17. Liver failure (Child-Pugh class C). 18. Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits). 19. Extreme aortic valve calcification and calcific asymmetry (if semiquantitively measured: grade 4, Agatston score: grade 4 AgS>5000 AU). 20. Aortic valve area of < 0.4 cm2. |
Country | Name | City | State |
---|---|---|---|
Greece | Department of Cardiology, Onassis Cardiac Surgery Center | Athens | |
Greece | First Department of Cardiology, University of Athens | Athens | Attiki |
Greece | Second Department of Cardiology, University Hospital of Ioannina | Ioannina | |
Israel | Heart Institute Hadassah Hebrew University Medical Center | Jerusalem |
Lead Sponsor | Collaborator |
---|---|
National and Kapodistrian University of Athens |
Greece, Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Device success | Device success, as designated by the VARC-2 criteria. | 30 days | |
Secondary | Death | Death during the hospitalization of the patient, as designated by the VARC-2 criteria. | 30 days | |
Secondary | Cerebrovascular accident | Cerebrovascular accident during and after the hospitalization of the patient, as designated by the VARC-2 criteria. | 30 days and 1 year | |
Secondary | New pacemaker implantation | New pacemaker implantation during the hospitalization of the patient, as designated by the VARC-2 criteria. | 30 days | |
Secondary | Vascular complications | Vascular complications during the hospitalization of the patient, as designated by the VARC-2 criteria. | 30 days | |
Secondary | Mortality | Death after discharge of the patient, as designated by the VARC-2 criteria. | after 30 days and at 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03186339 -
Validation of the "TASQ" in Patients Undergoing SAVR or TF-TAVI
|
||
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Terminated |
NCT02854319 -
REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System
|
N/A | |
Recruiting |
NCT05601453 -
The ReTAVI Prospective Observational Registry
|
||
Withdrawn |
NCT05481814 -
CPX in Paradoxical Low Flow Aortic Stenosis
|
||
Completed |
NCT02241109 -
Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity
|
N/A | |
Completed |
NCT01700439 -
Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve
|
N/A | |
Recruiting |
NCT04429035 -
SLOW-Slower Progress of caLcificatiOn With Vitamin K2
|
N/A | |
Completed |
NCT04103931 -
Impact of a Patient Decision Aid for Treatment of Aortic Stenosis
|
N/A | |
Completed |
NCT03950440 -
Assessing the Incidence of Postoperative Delirium Following Aortic Valve Replacement
|
||
Active, not recruiting |
NCT02661451 -
Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)
|
N/A | |
Completed |
NCT02758964 -
Evaluation of Cerebral Thrombembolism After TAVR
|
||
Completed |
NCT02792452 -
Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis
|
||
Completed |
NCT02847546 -
Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation
|
N/A | |
Not yet recruiting |
NCT02536703 -
Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population
|
Phase 3 | |
Not yet recruiting |
NCT02541877 -
Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve
|
Phase 3 | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Completed |
NCT02249000 -
BIOVALVE - I / II Clincial Investigation
|
N/A | |
Active, not recruiting |
NCT02080299 -
Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation
|
Phase 2 | |
Terminated |
NCT01939678 -
Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease
|